Fixing Off Target Effects Of CRISPR/Cas9
The simplicity and accessibility of CRISPR have given themselves the oxygen to spread like wildfire through the research community, but also have the undesirable effects. Recently, scientists have used it in clinical trials to delay or halt the production of lung cancer cells, but because of these concerns about the off-target effects of CRISPR / Cas9, scientists wonder how effective it will be in humans. This leads to another important question and concern, what the off-target effects will be in tests with people.
Potential / questionable mutant conclusions
Employees of Kellie A. Schaefer and Stanford have determined that the accuracy of CRISPR / Cas9 with regard to abnormal mutations needs to be further improved, especially when it comes to clinical therapies. Kellie A. Schaefer, Ph. D., Stanford University and colleagues from Howard Hughes and the Massachusetts General Hospital performed whole genome sequencing (WGS) on DNA isolated from two CRISPR-repaired mice (F03 and F05) and one uncorrected control. They said that the sequence found had an exceptionally high value of single nucleotide variations (SNVs) compared to the mean assumption that CRISPR causes mutations primarily in areas that are homologous to the sgRNA. Benjamin P. Kleinstiver Ph.D. of the Department of Molecular Pathology and Center for Cancer Research at the Massachusetts General Hospital and other researchers hypothesized that reducing the contact between iCas9 and the targeted DNA could help to reduce the off-target effects without compromising the interactions on the target. bring. bring. In the BioRxiv article by Wilson et al. It was noted that the Schaefer et al. Study was not technically decisive due to the small sample size. Curiously, one of Wilson's co-authors for BioRxiv, George Church, has a vested interest in the success of CRISPR technologies.